Regulator of calcineurin 2 (RCAN2)

Regulator of calcineurin 2 (RCAN2) is a member of the regulator of calcineurin protein family that acts primarily as an endogenous inhibitor of the Ca²⁺/calmodulin-dependent phosphatase calcineurin. RCAN2 directly binds the catalytic domain of calcineurin A, inhibiting calcineurin-mediated dephosphorylation of transcription factors such as NFAT, thereby affecting gene expression in multiple pathways. RCAN2 is most highly expressed in the brain, heart, kidney, skeletal muscle, and other organs, with expression responsive to hormonal changes and stress signals. It plays essential roles in calcium signaling, cilia formation and maintenance, appetite regulation, energy homeostasis, and bone development. Pathologically, abnormal RCAN2 expression or function has been implicated in Down syndrome, neurodegeneration, obesity, diabetes, cancer (especially through modulation of NFAT signaling), and bone disorders. While proposed as a therapeutic target for metabolic, neurodegenerative, and cancer indications, no approved drugs currently target RCAN2 directly. RCAN2 may also serve as a biomarker in research settings for metabolic disease and certain cancers[3][4][5][7][8].

Other names

Calcipressin-2DSCR1L1ZAKI4MCIP2Down syndrome candidate region 1-like 1Myocyte-enriched calcineurin-interacting protein 2Thyroid hormone-responsive protein ZAKI-4CSP2

Inhibits calcineurin by direct binding, blocking calcineurin-mediated dephosphorylation (primarily of NFAT). Competes with NFAT for calcineurin binding. Modulates nuclear translocation of transcription factors.